Sökning: onr:"swepub:oai:lup.lub.lu.se:1686aaa9-7dd3-458b-9214-7ca95c1b0f0e" > Melphalan, predniso...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04785naa a2200661 4500 | |
001 | oai:lup.lub.lu.se:1686aaa9-7dd3-458b-9214-7ca95c1b0f0e | |
003 | SwePub | |
008 | 160404s2016 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:133289284 | |
024 | 7 | a https://lup.lub.lu.se/record/85739672 URI |
024 | 7 | a https://doi.org/10.1182/blood-2015-11-6794152 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1332892842 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Zweegman, Sonja4 aut |
245 | 1 0 | a Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. |
264 | 1 | b American Society of Hematology,c 2016 |
520 | a The combination of melphalan, prednisone and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma (NDMM) who are ineligible for stem-cell transplantation. Long term treatment with thalidomide is hampered by neurotoxicity. Melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy showed promising results, without severe neuropathy emerging. We randomly assigned 668 NDMM patients, ineligible for stem-cell transplantation, between nine 4-weekly cycles of MPT followed by thalidomide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen with thalidomide being replaced by lenalidomide (MPR-R). This multicenter, open-label, randomised phase 3 trial was undertaken by HOVON and the NMSG. The primary endpoint was progression-free survival (PFS). The accrual for the study was completed in October 19, 2012. 318 patients were randomly assigned to receive MPT-T and 319 MPR-R. After a median follow up of 36 months PFS with MPT-T was 20 months (95% CI 18-23 months) versus 23 months (95% CI 19-27 months) with MPR-R (HR 0.87 [0.72-1.04], p=0.12). Response rates were similar, with ≥VGPR 47% and 45% respectively. Hematological toxicity was more pronounced with MPR-R, especially grade 3 and 4 neutropenia: 64 versus 27%. Neuropathy ≥ grade 3 was significantly higher in the MPT-T arm; 16% versus 2% in MPR-R, resulting in a significant shorter duration of maintenance therapy (5 versus 17 months in MPR-R), irrespective of age. MPR-R has no advantage over MPT-T concerning efficacy. The toxicity profile differed with clinically significant neuropathy during thalidomide maintenance versus myelosuppression with MPR. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a van der Holt, Bronno4 aut |
700 | 1 | a Mellqvist, Ulf-Henrik4 aut |
700 | 1 | a Salomo, Morten4 aut |
700 | 1 | a Bos, Gerard M J4 aut |
700 | 1 | a Levin, Mark-David4 aut |
700 | 1 | a Visser-Wisselaar, Heleen4 aut |
700 | 1 | a Hansson, Markusu Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)hema-mha |
700 | 1 | a van der Velden, Annette W G4 aut |
700 | 1 | a Deenik, Wendy4 aut |
700 | 1 | a Gruber, Astrid4 aut |
700 | 1 | a Coenen, Juleon L L M4 aut |
700 | 1 | a Plesner, Torben4 aut |
700 | 1 | a Klein, Saskia K4 aut |
700 | 1 | a Tanis, Bea C4 aut |
700 | 1 | a Szatkowski, Damian L4 aut |
700 | 1 | a Brouwer, Rolf E4 aut |
700 | 1 | a Westerman, Matthijs4 aut |
700 | 1 | a Leys, M Rineke B L4 aut |
700 | 1 | a Sinnige, Harm A M4 aut |
700 | 1 | a Haukås, Einar4 aut |
700 | 1 | a van der Hem, Klaas G4 aut |
700 | 1 | a Durian, Marc F4 aut |
700 | 1 | a Mattijssen, E Vera J M4 aut |
700 | 1 | a van de Donk, Niels W C J4 aut |
700 | 1 | a Stevens-Kroef, Marian J P L4 aut |
700 | 1 | a Sonneveld, Pieter4 aut |
700 | 1 | a Waage, Anders4 aut |
710 | 2 | a Avdelningen för hematologi och transfusionsmedicinb Institutionen för laboratoriemedicin4 org |
773 | 0 | t Bloodd : American Society of Hematologyg 127:9, s. 1109-1116q 127:9<1109-1116x 1528-0020x 0006-4971 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/26802176?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1182/blood-2015-11-679415y FULLTEXT |
856 | 4 | u https://ashpublications.org/blood/article-pdf/127/9/1109/1395773/1109.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/8573967 |
856 | 4 8 | u https://doi.org/10.1182/blood-2015-11-679415 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:133289284 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy